incb3344 profile

INCB3344: potent and selective small molecule CCR2 chemokine receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	10008367
CHEMBL ID	1289316
CHEMBL ID	2426341
SCHEMBL ID	747726
MeSH ID	M0492446

Synonym
HY-50674
incb 3344
gtpl777
incb3344
cid 10008367
n-(2-((3s,4s)-1-(cis-4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl)-4-ethoxypyrrolidin-3-ylamino)-2-oxoethyl)-3-(trifluoromethyl)benzamide
bdbm50331728
CHEMBL1289316 ,
incb-3344
CHEMBL2426341
n-(2-(((3s,4s)-1-(4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl)-4-ethoxypyrrolidin-3-yl)amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide
709018-37-1
CS-0347
cis-incb3344
CS-M1486
SCHEMBL747726
1262238-11-8
NCGC00378837-01
CS-0058750
HY-50674A
incb3344 r-isomer
benzamide, n-[2-[[(3r,4r)-1-[cis-4-(1,3-benzodioxol-5-yl)-4-hydroxycyclohexyl]-4-ethoxy-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)-, rel-
1285539-85-6
n-(2-(((3s,4s)-1-((1r,4s)-4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl)-4-ethoxypyrrolidin-3-yl)amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide
CS-13932
n-(2-(((3s,4s)-1-((1s,4r)-4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl)-4-ethoxypyrrolidin-3-yl)amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide
A906838
F82231
MS-30386
n-[2-[[(3s,4s)-1-[4-(1,3-benzodioxol-5-yl)-4-hydroxycyclohexyl]-4-ethoxypyrrolidin-3-yl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide
AKOS037649947
mzeosvpwmsefpw-xycdvdstsa-n
HY-77111
rel-n-[2-[[(3r,4r)-1-[cis-4-(1,3-benzodioxol-5-yl)-4-hydroxycyclohexyl]-4-ethoxy-3-pyrrolidinyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide
DTXSID701100838

Excerpt	Reference	Relevance
"INCB3344 treatment results in a dose-dependent inhibition of macrophage influx in a mouse model of delayed-type hypersensitivity."	( Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. Baribaud, F; Brodmerkel, CM; Burn, T; Collier, P; Collins, R; Covington, M; Diamond, S; Feldman, P; Friedman, S; Gallagher, K; Gu, X; Hall, L; Hollis, G; Huber, R; Leffet, L; Newton, RC; Scherle, P; Shin, N; Solomon, K; Stow, M; Thomas, B; Vaddi, K; Wang, A; Xue, CB; Yeleswaram, S, 2005)	1.27
"INCB3344 treatment significantly inhibited macrophage infiltration into the laser-irradiated area (p<0.001), and suppressed the expression of VEGF protein (p = 0.012), VEGF mRNA in infiltrating macrophages (p<0.001) and the phosphorylation of ERK1/2 (p<0.001)."	( Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344. Kamei, M; Matsumura, N; Nishida, K; Sakaguchi, H; Sakimoto, S; Suzuki, M; Xie, P, 2011)	1.31
"Mice treated with INCB3344 exhibited markedly worse functional outcomes and larger infarct volumes, in association with reduced M2 polarization and increased peroxynitrite production in macrophages, compared with vehicle-treated mice."	( Evidence That Ly6C(hi) Monocytes are Protective in Acute Ischemic Stroke by Promoting M2 Macrophage Polarization. Broughton, BR; Chu, HX; Drummond, GR; Kim, HA; Lee, S; Sobey, CG, 2015)	0.74

Excerpt	Reference	Relevance
" INCB3344 possesses good oral bioavailability and systemic exposure in rodents that allows in vivo pharmacological studies."	( Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. Baribaud, F; Brodmerkel, CM; Burn, T; Collier, P; Collins, R; Covington, M; Diamond, S; Feldman, P; Friedman, S; Gallagher, K; Gu, X; Hall, L; Hollis, G; Huber, R; Leffet, L; Newton, RC; Scherle, P; Shin, N; Solomon, K; Stow, M; Thomas, B; Vaddi, K; Wang, A; Xue, CB; Yeleswaram, S, 2005)	1.46
" INCB3344 exhibited >100-fold selectivity over other homologous chemokine receptors, a free fraction of 24% in human serum and 15% in mouse serum, and an oral bioavailability of 47% in mice, suitable as a tool compound for target validation in rodent models."	( Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2. Anand, R; Brodmerkel, CM; Cao, G; Covington, M; Diamond, S; Feng, H; Friedman, S; Glenn, J; Han, Q; Hollis, G; Huang, T; Kong, L; Li, M; Meloni, D; Metcalf, B; Newton, R; Robinson, DJ; Scherle, P; Shao, L; Storace, L; Vaddi, K; Wang, A; Xia, M; Xue, CB; Yeleswaram, S; Zhang, K; Zhang, Y; Zheng, C, 2010)	1.64
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" We demonstrate that therapeutic dosing of INCB3344 significantly reduces disease in mice subjected to experimental autoimmune encephalomyelitis, a model of multiple sclerosis, as well as a rat model of inflammatory arthritis."	( Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. Baribaud, F; Brodmerkel, CM; Burn, T; Collier, P; Collins, R; Covington, M; Diamond, S; Feldman, P; Friedman, S; Gallagher, K; Gu, X; Hall, L; Hollis, G; Huber, R; Leffet, L; Newton, RC; Scherle, P; Shin, N; Solomon, K; Stow, M; Thomas, B; Vaddi, K; Wang, A; Xue, CB; Yeleswaram, S, 2005)	0.81

Protein Targets (15)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	0.3379	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	3.3786	0.0010	8.3798	61.1304	AID1645840
Interferon beta	Homo sapiens (human)	Potency	11.9877	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	11.9877	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
C-C chemokine receptor type 2	Rattus norvegicus (Norway rat)	IC50 (µMol)	7.3000	7.3000	7.3000	7.3000	AID539996
C-C chemokine receptor type 2	Homo sapiens (human)	IC50 (µMol)	0.0045	0.0000	0.6736	6.6990	AID539989; AID539991
C-C chemokine receptor type 1	Mus musculus (house mouse)	IC50 (µMol)	1.0000	0.0058	0.9142	5.0000	AID539998
C-C chemokine receptor type 5	Mus musculus (house mouse)	IC50 (µMol)	3.0000	0.0003	0.0017	0.0052	AID539999
C-C chemokine receptor type 2	Mus musculus (house mouse)	IC50 (µMol)	0.0086	0.0078	0.0086	0.0095	AID539990; AID539992
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)	IC50 (µMol)	13.0000	0.0009	1.9014	10.0000	AID539995
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
C-C motif chemokine 2	Homo sapiens (human)	Kd	0.0008	0.0002	0.0008	0.0012	AID771593; AID771594; AID771595; AID771596
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (149)

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
angiogenesis	C-C motif chemokine 2	Homo sapiens (human)
monocyte chemotaxis	C-C motif chemokine 2	Homo sapiens (human)
protein phosphorylation	C-C motif chemokine 2	Homo sapiens (human)
chemotaxis	C-C motif chemokine 2	Homo sapiens (human)
humoral immune response	C-C motif chemokine 2	Homo sapiens (human)
cytoskeleton organization	C-C motif chemokine 2	Homo sapiens (human)
cell adhesion	C-C motif chemokine 2	Homo sapiens (human)
signal transduction	C-C motif chemokine 2	Homo sapiens (human)
cell surface receptor signaling pathway	C-C motif chemokine 2	Homo sapiens (human)
G protein-coupled receptor signaling pathway	C-C motif chemokine 2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	C-C motif chemokine 2	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	C-C motif chemokine 2	Homo sapiens (human)
regulation of cell shape	C-C motif chemokine 2	Homo sapiens (human)
response to bacterium	C-C motif chemokine 2	Homo sapiens (human)
animal organ morphogenesis	C-C motif chemokine 2	Homo sapiens (human)
viral genome replication	C-C motif chemokine 2	Homo sapiens (human)
cytokine-mediated signaling pathway	C-C motif chemokine 2	Homo sapiens (human)
sensory perception of pain	C-C motif chemokine 2	Homo sapiens (human)
cellular homeostasis	C-C motif chemokine 2	Homo sapiens (human)
negative regulation of glial cell apoptotic process	C-C motif chemokine 2	Homo sapiens (human)
helper T cell extravasation	C-C motif chemokine 2	Homo sapiens (human)
negative regulation of neuron apoptotic process	C-C motif chemokine 2	Homo sapiens (human)
astrocyte cell migration	C-C motif chemokine 2	Homo sapiens (human)
cellular response to fibroblast growth factor stimulus	C-C motif chemokine 2	Homo sapiens (human)
macrophage chemotaxis	C-C motif chemokine 2	Homo sapiens (human)
positive regulation of T cell activation	C-C motif chemokine 2	Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic process	C-C motif chemokine 2	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	C-C motif chemokine 2	Homo sapiens (human)
cellular response to lipopolysaccharide	C-C motif chemokine 2	Homo sapiens (human)
cellular response to type II interferon	C-C motif chemokine 2	Homo sapiens (human)
cellular response to interleukin-1	C-C motif chemokine 2	Homo sapiens (human)
cellular response to tumor necrosis factor	C-C motif chemokine 2	Homo sapiens (human)
positive regulation of calcium ion import	C-C motif chemokine 2	Homo sapiens (human)
positive regulation of NMDA glutamate receptor activity	C-C motif chemokine 2	Homo sapiens (human)
negative regulation of vascular endothelial cell proliferation	C-C motif chemokine 2	Homo sapiens (human)
negative regulation of G1/S transition of mitotic cell cycle	C-C motif chemokine 2	Homo sapiens (human)
positive regulation of endothelial cell apoptotic process	C-C motif chemokine 2	Homo sapiens (human)
positive regulation of apoptotic cell clearance	C-C motif chemokine 2	Homo sapiens (human)
negative regulation of natural killer cell chemotaxis	C-C motif chemokine 2	Homo sapiens (human)
positive regulation of cell migration	C-C motif chemokine 2	Homo sapiens (human)
positive regulation of GTPase activity	C-C motif chemokine 2	Homo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptide	C-C motif chemokine 2	Homo sapiens (human)
inflammatory response	C-C motif chemokine 2	Homo sapiens (human)
eosinophil chemotaxis	C-C motif chemokine 2	Homo sapiens (human)
chemokine-mediated signaling pathway	C-C motif chemokine 2	Homo sapiens (human)
cytokine-mediated signaling pathway	C-C chemokine receptor type 2	Homo sapiens (human)
blood vessel remodeling	C-C chemokine receptor type 2	Homo sapiens (human)
dendritic cell chemotaxis	C-C chemokine receptor type 2	Homo sapiens (human)
monocyte chemotaxis	C-C chemokine receptor type 2	Homo sapiens (human)
regulation of T cell cytokine production	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of T-helper 1 type immune response	C-C chemokine receptor type 2	Homo sapiens (human)
negative regulation of type 2 immune response	C-C chemokine receptor type 2	Homo sapiens (human)
intracellular calcium ion homeostasis	C-C chemokine receptor type 2	Homo sapiens (human)
chemotaxis	C-C chemokine receptor type 2	Homo sapiens (human)
humoral immune response	C-C chemokine receptor type 2	Homo sapiens (human)
cellular defense response	C-C chemokine receptor type 2	Homo sapiens (human)
negative regulation of adenylate cyclase activity	C-C chemokine receptor type 2	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	C-C chemokine receptor type 2	Homo sapiens (human)
response to wounding	C-C chemokine receptor type 2	Homo sapiens (human)
regulation of vascular endothelial growth factor production	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of T cell chemotaxis	C-C chemokine receptor type 2	Homo sapiens (human)
negative regulation of angiogenesis	C-C chemokine receptor type 2	Homo sapiens (human)
sensory perception of pain	C-C chemokine receptor type 2	Homo sapiens (human)
cellular homeostasis	C-C chemokine receptor type 2	Homo sapiens (human)
hemopoiesis	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of type II interferon production	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of interleukin-2 production	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	C-C chemokine receptor type 2	Homo sapiens (human)
monocyte extravasation	C-C chemokine receptor type 2	Homo sapiens (human)
T-helper 17 cell chemotaxis	C-C chemokine receptor type 2	Homo sapiens (human)
negative regulation of eosinophil degranulation	C-C chemokine receptor type 2	Homo sapiens (human)
regulation of T cell differentiation	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of alpha-beta T cell proliferation	C-C chemokine receptor type 2	Homo sapiens (human)
homeostasis of number of cells within a tissue	C-C chemokine receptor type 2	Homo sapiens (human)
regulation of inflammatory response	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of inflammatory response	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of T cell activation	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	C-C chemokine receptor type 2	Homo sapiens (human)
leukocyte adhesion to vascular endothelial cell	C-C chemokine receptor type 2	Homo sapiens (human)
chemokine-mediated signaling pathway	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of monocyte chemotaxis	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of immune complex clearance by monocytes and macrophages	C-C chemokine receptor type 2	Homo sapiens (human)
inflammatory response to wounding	C-C chemokine receptor type 2	Homo sapiens (human)
neutrophil clearance	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of leukocyte tethering or rolling	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of NMDA glutamate receptor activity	C-C chemokine receptor type 2	Homo sapiens (human)
macrophage migration	C-C chemokine receptor type 2	Homo sapiens (human)
regulation of macrophage migration	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of thymocyte migration	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of monocyte extravasation	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of CD8-positive, alpha-beta T cell extravasation	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of astrocyte chemotaxis	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of hematopoietic stem cell migration	C-C chemokine receptor type 2	Homo sapiens (human)
cell chemotaxis	C-C chemokine receptor type 2	Homo sapiens (human)
calcium-mediated signaling	C-C chemokine receptor type 2	Homo sapiens (human)
inflammatory response	C-C chemokine receptor type 2	Homo sapiens (human)
immune response	C-C chemokine receptor type 2	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	C-C chemokine receptor type 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by hormone	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of DNA-templated transcription	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion homeostasis	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cardiac muscle contraction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane depolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potential	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
negative regulation of potassium ion export across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
potassium ion import across plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (39)

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein kinase activity	C-C motif chemokine 2	Homo sapiens (human)
signaling receptor binding	C-C motif chemokine 2	Homo sapiens (human)
protein binding	C-C motif chemokine 2	Homo sapiens (human)
CCR2 chemokine receptor binding	C-C motif chemokine 2	Homo sapiens (human)
chemokine activity	C-C motif chemokine 2	Homo sapiens (human)
CCR chemokine receptor binding	C-C motif chemokine 2	Homo sapiens (human)
chemokine receptor activity	C-C chemokine receptor type 2	Homo sapiens (human)
protein binding	C-C chemokine receptor type 2	Homo sapiens (human)
CCR2 chemokine receptor binding	C-C chemokine receptor type 2	Homo sapiens (human)
chemokine (C-C motif) ligand 2 binding	C-C chemokine receptor type 2	Homo sapiens (human)
chemokine (C-C motif) ligand 12 binding	C-C chemokine receptor type 2	Homo sapiens (human)
chemokine (C-C motif) ligand 7 binding	C-C chemokine receptor type 2	Homo sapiens (human)
identical protein binding	C-C chemokine receptor type 2	Homo sapiens (human)
C-C chemokine binding	C-C chemokine receptor type 2	Homo sapiens (human)
C-C chemokine receptor activity	C-C chemokine receptor type 2	Homo sapiens (human)
transcription cis-regulatory region binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
delayed rectifier potassium channel activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
ubiquitin protein ligase binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
identical protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
protein homodimerization activity	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
C3HC4-type RING finger domain binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
scaffold protein binding	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular region	C-C motif chemokine 2	Homo sapiens (human)
extracellular space	C-C motif chemokine 2	Homo sapiens (human)
fibrillar center	C-C chemokine receptor type 2	Homo sapiens (human)
cytoplasm	C-C chemokine receptor type 2	Homo sapiens (human)
cytosol	C-C chemokine receptor type 2	Homo sapiens (human)
plasma membrane	C-C chemokine receptor type 2	Homo sapiens (human)
membrane	C-C chemokine receptor type 2	Homo sapiens (human)
dendrite	C-C chemokine receptor type 2	Homo sapiens (human)
neuronal cell body	C-C chemokine receptor type 2	Homo sapiens (human)
perikaryon	C-C chemokine receptor type 2	Homo sapiens (human)
perinuclear region of cytoplasm	C-C chemokine receptor type 2	Homo sapiens (human)
cytoplasm	C-C chemokine receptor type 2	Homo sapiens (human)
external side of plasma membrane	C-C chemokine receptor type 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
cell surface	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
perinuclear region of cytoplasm	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
voltage-gated potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
inward rectifier potassium channel complex	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
plasma membrane	Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (29)

Assay ID	Title	Year	Journal	Article
AID539993	Protein binding in human serum assessed as unbound fraction	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID539989	Displacement of [125I]MCP1 from human CCR2 after 30 mins by gamma counter	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID539997	Inhibition of cynomolgus CCR2	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID539990	Displacement of [125I]MCP1 from mouse CCR2 after 30 mins by gamma counter	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID539995	Inhibition of human ERG	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID540003	Cmax in CD-1 mouse at 10 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID540000	Clearance in CD-1 mouse at 5 mg/kg, iv	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID539992	Antagonist activity at mouse CCR2 assessed as inhibition of MCP1 induced chemotaxis after 30 mins	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID539991	Antagonist activity at human CCR2 assessed as inhibition of MCP1 induced chemotaxis after 30 mins	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID540002	Half life in CD-1 mouse at 5 mg/kg, iv	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID539994	Protein binding in mouse serum assessed as unbound fraction	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID540007	AUC in BALB/c mouse at 10 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID540006	Cmax in BALB/c mouse at 10 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID540001	Volume of distribution at steady state in CD-1 mouse at 5 mg/kg, iv	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID540004	AUC in CD-1 mouse at 10 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID539999	Inhibition of mouse CCR5	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID539998	Inhibition of mouse CCR1	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID539996	Inhibition of rat CCR2	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID540005	Oral bioavailability in CD-1 mouse at 10 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24	Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346744	Mouse CCR2 (Chemokine receptors)	2005	Journal of immunology (Baltimore, Md. : 1950), Oct-15, Volume: 175, Issue:8	Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.
AID771594	Displacement of [3H]INCB3344 from human CCR2 receptor expressed in human U2OS cell membranes assessed as association and dissociation of radioligand	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Structure-kinetic relationships--an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists.
AID771595	Displacement of [3H]INCB3344 from human CCR2 receptor expressed in human U2OS cell membranes	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Structure-kinetic relationships--an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists.
AID771593	Displacement of [3H]INCB3344 from human CCR2 receptor expressed in human U2OS cell membranes assessed as association and dissociation of compound by competition association assay	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Structure-kinetic relationships--an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists.
AID771596	Displacement of [3H]INCB3344 from human CCR2 receptor expressed in human U2OS cell membranes by saturation binding assay	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Structure-kinetic relationships--an overlooked parameter in hit-to-lead optimization: a case of cyclopentylamines as chemokine receptor 2 antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (13.04)	29.6817
2010's	15 (65.22)	24.3611
2020's	5 (21.74)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	23 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	2.04	1	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
desoxycorticosterone Desoxycorticosterone: A steroid metabolite that is the 11-deoxy derivative of CORTICOSTERONE and the 21-hydroxy derivative of PROGESTERONE	2.07	1	20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; mineralocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
substance p [no description available]	2.04	1	peptide	neurokinin-1 receptor agonist; neurotransmitter; vasodilator agent

Condition	Relationship Strength	Studies
Adjuvant Arthritis [description not available]	2.02	1
Allergic Encephalomyelitis [description not available]	2.02	1
Congenital Zika Syndrome [description not available]	2.25	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.11	4
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	2.25	1
Diabetic Glomerulosclerosis [description not available]	2.31	1
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.31	1
Alloxan Diabetes [description not available]	2.21	1
Cirrhosis [description not available]	2.21	1
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	2.21	1
Diabetic Cardiomyopathies Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.	2.21	1
Delayed Effects, Prenatal Exposure [description not available]	2.25	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.25	1
Allodynia [description not available]	3.2	5
Innate Inflammatory Response [description not available]	2.53	2
Ache [description not available]	2.31	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	2.53	2
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	2.31	1
Nerve Pain [description not available]	2.79	3
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	2.79	3
ADPKD [description not available]	2.17	1
Polycystic Kidney, Autosomal Dominant Kidney disorders with autosomal dominant inheritance and characterized by multiple CYSTS in both KIDNEYS with progressive deterioration of renal function.	2.17	1
Craniofacial Pain [description not available]	2.1	1
Facial Pain Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.	2.1	1
Apoplexy [description not available]	2.11	1
Cerebral Ischemia [description not available]	2.52	2
Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.	2.52	2
Stroke A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)	2.11	1
Cerebral Infarction, Middle Cerebral Artery [description not available]	2.13	1
Infarction, Middle Cerebral Artery NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.	2.13	1
Chronic Illness [description not available]	2.06	1
Peripheral Nerve Injury [description not available]	2.06	1
Constriction, Pathological [description not available]	2.06	1
Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).	2.06	1
Constriction, Pathologic The condition of an anatomical structure's being constricted beyond normal dimensions.	2.06	1
Peripheral Nerve Injuries Injuries to the PERIPHERAL NERVES.	2.06	1
Choroid Neovascularization [description not available]	2.06	1
Blood Pressure, High [description not available]	2.07	1
Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.	2.07	1

incb3344

Description

Cross-References

Synonyms (35)

Research Excerpts

Treatment

Bioavailability

Dosage Studied

Protein Targets (15)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (149)

Molecular Functions (39)

Ceullar Components (28)

Bioassays (29)

Research

Studies (23)

Market Indicators

Research Demand Index: 21.25

Study Types

incb3344

Description

Cross-References

Synonyms (35)

Research Excerpts

Treatment

Bioavailability

Dosage Studied

Protein Targets (15)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (149)

Molecular Functions (39)

Ceullar Components (28)

Bioassays (29)

Research

Studies (23)

Market Indicators

Research Demand Index: 21.25

Study Types

Related Drugs (3)

Related Conditions (39)